Annual CFO
-$30.68 M
-$3.93 M-14.69%
December 31, 2023
Summary
- As of March 10, 2025, AVTX annual cash flow from operations is -$30.68 million, with the most recent change of -$3.93 million (-14.69%) on December 31, 2023.
- During the last 3 years, AVTX annual CFO has risen by +$9.86 million (+24.32%).
- AVTX annual CFO is now -343.90% below its all-time high of $12.58 million, reached on December 31, 2017.
Performance
AVTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$11.53 M
+$4.76 M+29.21%
September 30, 2024
Summary
- As of March 10, 2025, AVTX quarterly cash flow from operations is -$11.53 million, with the most recent change of +$4.76 million (+29.21%) on September 30, 2024.
- Over the past year, AVTX quarterly CFO has stayed the same.
- AVTX quarterly CFO is now -160.28% below its all-time high of $19.12 million, reached on September 30, 2017.
Performance
AVTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$36.78 M
-$4.69 M-14.62%
September 30, 2024
Summary
- As of March 10, 2025, AVTX TTM cash flow from operations is -$36.78 million, with the most recent change of -$4.69 million (-14.62%) on September 30, 2024.
- Over the past year, AVTX TTM CFO has stayed the same.
- AVTX TTM CFO is now -330.44% below its all-time high of $15.96 million, reached on June 30, 2018.
Performance
AVTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
AVTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.7% | 0.0% | 0.0% |
| 3 y3 years | +24.3% | 0.0% | 0.0% |
| 5 y5 years | -880.8% | 0.0% | 0.0% |
AVTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -14.7% | +56.7% | -301.3% | +32.6% | -90.6% | +48.1% |
| 5 y | 5-year | -60.3% | +56.7% | -301.3% | +39.9% | -92.2% | +48.1% |
| alltime | all time | -343.9% | +56.7% | -160.3% | +39.9% | -330.4% | +48.1% |
Avalo Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$11.53 M(-29.2%) | -$36.78 M(+14.6%) |
| Jun 2024 | - | -$16.28 M(+162.5%) | -$32.09 M(+19.6%) |
| Mar 2024 | - | -$6.20 M(+124.2%) | -$26.83 M(-12.5%) |
| Dec 2023 | -$30.68 M(+14.7%) | -$2.77 M(-59.5%) | -$30.68 M(-3.7%) |
| Sep 2023 | - | -$6.84 M(-38.0%) | -$31.85 M(+65.1%) |
| Jun 2023 | - | -$11.03 M(+9.7%) | -$19.29 M(-7.0%) |
| Mar 2023 | - | -$10.05 M(+155.1%) | -$20.74 M(-22.5%) |
| Dec 2022 | -$26.75 M(-62.3%) | -$3.94 M(-168.8%) | -$26.75 M(-33.0%) |
| Sep 2022 | - | $5.73 M(-145.9%) | -$39.91 M(-35.6%) |
| Jun 2022 | - | -$12.47 M(-22.4%) | -$61.93 M(-9.8%) |
| Mar 2022 | - | -$16.07 M(-6.0%) | -$68.64 M(-3.2%) |
| Dec 2021 | -$70.89 M(+74.9%) | -$17.10 M(+5.0%) | -$70.89 M(+4.0%) |
| Sep 2021 | - | -$16.29 M(-15.1%) | -$68.17 M(+6.9%) |
| Jun 2021 | - | -$19.19 M(+4.8%) | -$63.75 M(+20.0%) |
| Mar 2021 | - | -$18.32 M(+27.4%) | -$53.12 M(+31.0%) |
| Dec 2020 | -$40.54 M(+111.9%) | -$14.38 M(+21.1%) | -$40.54 M(+45.6%) |
| Sep 2020 | - | -$11.87 M(+38.7%) | -$27.84 M(+18.0%) |
| Jun 2020 | - | -$8.55 M(+49.1%) | -$23.59 M(+8.4%) |
| Mar 2020 | - | -$5.74 M(+241.5%) | -$21.75 M(+13.7%) |
| Dec 2019 | -$19.13 M | -$1.68 M(-77.9%) | -$19.13 M(-1.5%) |
| Sep 2019 | - | -$7.62 M(+13.4%) | -$19.43 M(+57.3%) |
| Jun 2019 | - | -$6.72 M(+115.2%) | -$12.35 M(+106.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$3.12 M(+58.0%) | -$5.97 M(+90.8%) |
| Dec 2018 | -$3.13 M(-124.9%) | -$1.98 M(+267.0%) | -$3.13 M(-15.5%) |
| Sep 2018 | - | -$538.30 K(+61.3%) | -$3.70 M(-123.2%) |
| Jun 2018 | - | -$333.70 K(+19.0%) | $15.96 M(+9.8%) |
| Mar 2018 | - | -$280.40 K(-89.0%) | $14.53 M(+15.6%) |
| Dec 2017 | $12.58 M(-186.3%) | -$2.55 M(-113.3%) | $12.58 M(+10.2%) |
| Sep 2017 | - | $19.12 M(-1187.1%) | $11.41 M(-202.4%) |
| Jun 2017 | - | -$1.76 M(-21.3%) | -$11.14 M(-15.0%) |
| Mar 2017 | - | -$2.24 M(-39.8%) | -$13.10 M(-10.1%) |
| Dec 2016 | -$14.57 M(+43.4%) | -$3.71 M(+8.1%) | -$14.57 M(+1.1%) |
| Sep 2016 | - | -$3.43 M(-7.7%) | -$14.41 M(+12.7%) |
| Jun 2016 | - | -$3.72 M(+0.4%) | -$12.79 M(+18.4%) |
| Mar 2016 | - | -$3.71 M(+4.5%) | -$10.80 M(+6.3%) |
| Dec 2015 | -$10.16 M(-34.5%) | -$3.55 M(+95.5%) | -$10.16 M(-4.0%) |
| Sep 2015 | - | -$1.81 M(+4.8%) | -$10.58 M(-33.3%) |
| Jun 2015 | - | -$1.73 M(-43.6%) | -$15.87 M(-3.1%) |
| Mar 2015 | - | -$3.07 M(-22.6%) | -$16.38 M(+5.5%) |
| Dec 2014 | -$15.52 M(+35.1%) | -$3.97 M(-44.1%) | -$15.52 M(+34.3%) |
| Sep 2014 | - | -$7.10 M(+217.2%) | -$11.55 M(+159.5%) |
| Jun 2014 | - | -$2.24 M(+1.2%) | -$4.45 M(+101.2%) |
| Mar 2014 | - | -$2.21 M | -$2.21 M |
| Dec 2013 | -$11.49 M | - | - |
FAQ
- What is Avalo Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Avalo Therapeutics?
- What is Avalo Therapeutics annual CFO year-on-year change?
- What is Avalo Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Avalo Therapeutics?
- What is Avalo Therapeutics quarterly CFO year-on-year change?
- What is Avalo Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Avalo Therapeutics?
- What is Avalo Therapeutics TTM CFO year-on-year change?
What is Avalo Therapeutics annual cash flow from operations?
The current annual CFO of AVTX is -$30.68 M
What is the all time high annual CFO for Avalo Therapeutics?
Avalo Therapeutics all-time high annual cash flow from operations is $12.58 M
What is Avalo Therapeutics annual CFO year-on-year change?
Over the past year, AVTX annual cash flow from operations has changed by -$3.93 M (-14.69%)
What is Avalo Therapeutics quarterly cash flow from operations?
The current quarterly CFO of AVTX is -$11.53 M
What is the all time high quarterly CFO for Avalo Therapeutics?
Avalo Therapeutics all-time high quarterly cash flow from operations is $19.12 M
What is Avalo Therapeutics quarterly CFO year-on-year change?
Over the past year, AVTX quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Avalo Therapeutics TTM cash flow from operations?
The current TTM CFO of AVTX is -$36.78 M
What is the all time high TTM CFO for Avalo Therapeutics?
Avalo Therapeutics all-time high TTM cash flow from operations is $15.96 M
What is Avalo Therapeutics TTM CFO year-on-year change?
Over the past year, AVTX TTM cash flow from operations has changed by $0.00 (0.00%)